Roche rejigs UK comms for cancer drug portfolio
Roche is to shake up UK product comms within its weighty cancer drug portfolio. An agency pitch for MabThera is on the cards and the firm has brought in fresh backing for Avastin.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>